Stručni rad
https://doi.org/10.20471/acc.2022.61.s3.13
Genomics of Prostate Cancer: Clinical Utility and Challenges
Ivan Šamija
orcid.org/0000-0002-5633-5745
; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; Department of Immunology, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
Ana Fröbe
; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
Sažetak
The studying of prostate cancer genomics is important for understanding prostate
cancer biology, it can provide clinically relevant stratification into subtypes, the development of new
prognostic and predictive markers in the context of precision medicine, and the development of new
targeted therapies. Recent studies have provided detailed insight into genomics, epigenomics and proteomics
of prostate cancer, both primary and metastatic castration-resistant (mCRPC). Many mutations
have been discovered, both those that occur early in the carcinogenesis and progression as well as
those responsible for the resistance to therapy occurring later under the influence of treatment. A large
number of characteristic mutated signaling pathways has been identified, e.g. the mutations in DNA
repair pathway were found in 23% of mCRPC, which suggests potential response to PARP inhibitors.
Multifocality and intralesional genomic heterogeneity of prostate cancer make the clinical application
of genomics complicated. Although a great progress was made in understanding prostate cancer genomic,
and clinical studies related to its routine application are ongoing, prostate cancer genomics still
needs to find its standard wide routine application in patients with prostate cancer.
Ključne riječi
Prostate Cancer; Genomics; Tumor Biomarkers; Genetic Heterogeneity
Hrčak ID:
286377
URI
Datum izdavanja:
1.10.2022.
Posjeta: 1.427 *